Cian Healthcare Limited has announced significant board changes following the approval of its resolution plan by the National Company Law Tribunal (NCLT). The company disclosed the appointment of four new directors to its interim board, marking a crucial step in its corporate restructuring process under the Insolvency and Bankruptcy Code, 2016.

Resolution Plan Implementation Committee Approves New Board

The Resolution Plan Implementation Committee, in its meeting held on January 09, 2026, from 03:00 P.M. to 3:46 P.M. (IST) through video conferencing, considered and approved the nomination and appointment of the new board members. This decision follows the NCLT order dated December 18, 2025, which approved the resolution plan submitted by the Successful Resolution Applicant, Mr. Pradeep Kumar Jain.

The newly appointed directors and their designations are:

Board Powers and Implementation Timeline

The interim board's powers will remain suspended during the Resolution Plan Implementation Period, which commenced from the date of the NCLT Order and will continue until the Resolution Plan Closure Date. During this period, all board powers will be exercised by the Implementation Committee in accordance with the NCLT Order provisions.

Upon reaching the Resolution Plan Closure Date, the interim board will be granted full powers under the Companies Act, 2013, Listing Regulations, and other applicable regulatory provisions. Subsequently, the Implementation Committee will cease to have authority over the interim board.

Director Profiles and Qualifications

Mr. Pradeep Kumar Jain, appointed as Promoter and Non-Executive Director effective January 09, 2026, brings over 25 years of pharmaceutical industry experience. He holds a bachelor's degree in production management from the National Technical University "Kharkiv Polytechnic Institute" and an MBA followed by a PhD from Simon Kuznets Kharkiv National University of Economics. He has been instrumental in establishing Ananta Medicare Limited's operations and driving international expansion in Eastern Europe and CIS markets.

Mr. Rajesh Jain, also appointed as Promoter and Non-Executive Director from January 09, 2026, specializes in project management and production optimization within the pharmaceutical industry. He holds a Master of Pharmacy from Punjab Technical University (2013) and a Bachelor of Pharmacy from the University of Rajasthan (1995), while currently pursuing a PhD. His professional experience spans pharmaceuticals, retail, wholesale, manufacturing, laboratory services, and marketing since 1995.

Mr. Manish Goswami assumes the role of Independent Non-Executive Director for a five-year term starting January 09, 2026. With over two decades of pharmaceutical industry experience, he is a registered Vaidya with the Punjab Ayurvedic and Unani Systems of Medicine Board. He holds a PhD from North Gujarat University, focusing on "Studies and Design of Transdermal Drug Delivery Systems for Antiasthmatics," and has served as Director at the University Institute of Pharma Sciences and University Institute of Allied Health Sciences.

Mr. Anjani Misra joins as Independent Non-Executive Director for a five-year term from January 09, 2026. He brings 26 years of experience from the Reserve Bank of India, where he served as General Manager for over a decade. His expertise includes Rural Planning and Credit, Department of Supervision oversight, and serving as compounding authority under the Foreign Exchange Management Act, 1999.

Regulatory Compliance and Disclosures

The company confirmed that none of the proposed directors are debarred from holding directorship positions by SEBI or any other regulatory authority. The appointments comply with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, along with relevant SEBI circulars and the Companies Act, 2013.

Mr. Pradeep Kumar Jain and Mr. Rajesh Jain are disclosed as relatives under Section 2(77) of the Companies Act, 2013, and Regulation 2(zd) of the SEBI Listing Regulations. The other two independent directors have no disclosed relationships with existing board members.

Cian Healthcare Limited's Resolution Plan Implementation Committee has made significant corporate restructuring decisions following the National Company Law Tribunal's approval of its resolution plan. The committee meeting held on January 09, 2026, addressed key aspects of the company's capital restructuring and board reconstitution under the Insolvency and Bankruptcy Code framework.

Record Date Declaration

The Implementation Committee has declared January 16, 2026 as the record date for the reduction, cancellation, and extinguishment of existing paid-up equity share capital held by erstwhile promoters and existing public shareholders. This step forms a crucial part of the resolution plan implementation process approved by the NCLT on December 18, 2025.

Board Reconstitution

The committee approved the appointment of four new directors to form the interim board of directors:

The interim board's powers will remain suspended during the Resolution Plan Implementation Period, with all board powers being exercised by the Implementation Committee until the Resolution Plan Closure Date.

Fresh Equity Issuance

The committee approved the issuance of 2,37,50,000 fresh equity shares on a preferential basis to new promoters. Each share carries a face value of ₹10.00, bringing the total issuance value to ₹23,75,00,000.

Shareholding Distribution

The fresh equity shares will rank pari-passu with existing equity shares in all respects. Following this preferential allotment, the company's total issued, subscribed, and paid-up equity share capital will comprise 2,50,00,000 equity shares with a face value of ₹10.00 each, aggregating to ₹25,00,00,000.

Regulatory Compliance

All decisions were made in compliance with Regulation 30 of the SEBI Listing Regulations, relevant SEBI circulars, provisions of the Insolvency and Bankruptcy Code, and the NCLT order dated December 18, 2025. The company has committed to keeping stakeholders and regulatory authorities informed of further material developments in the resolution plan implementation process.

The Implementation Committee meeting commenced at 3:00 PM IST and concluded at 3:46 PM IST on January 09, 2026, conducted through video-conferencing under the chairmanship of Roshen Chordiya, the erstwhile Resolution Professional.